<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910308</url>
  </required_header>
  <id_info>
    <org_study_id>252575</org_study_id>
    <nct_id>NCT04910308</nct_id>
  </id_info>
  <brief_title>RAdiotherapy With FDG-PET Guided Dose-PAINTing for Primary Head and Neck</brief_title>
  <acronym>RADPAINT-2</acronym>
  <official_title>RAdiotherapy With FDG-PET Guided Dose-PAINTing for Primary Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in&#xD;
      volumetric-arc radiotherapy (VMAT) for head and neck cancer. This trial (RADPAINT)&#xD;
      investigates the safety of FDG-PET guided radiotherapy using VMAT dose-painting by contours&#xD;
      for patients with head and neck cancer of poor prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, radiotherapy is planned using 18F-FDG PET/CT (18F-2-fluoro-2-deoxy-D-glucose&#xD;
      fluorodeoxyglucose positron emission tomography) making one experimental &quot;dose-painting by&#xD;
      contours&quot; SIB (simultaneous integrated boost) plan with a maximum point dose of 83 Gy. The&#xD;
      participants will be given 73 Gy and 78 Gy minimum doses to two GTVs (gross tumor volumes&#xD;
      inside the conventional GTV (68 Gy). GTV_73Gy and GTV_78Gy are determined from the SUV&#xD;
      (standardized uptake values) from the 18F-FDG PET/CT according to the formula proposed by the&#xD;
      Ghent group (Van der Straeten et al, R&amp;O -06). It is expected to keep the level of normal&#xD;
      tissue side-effects within or slightly above the level of conventional radiotherapy (i.e.&#xD;
      maximum dose of 68 Gy).&#xD;
&#xD;
      In addition to the routine follow-up, the participants will be examined with 18F-FDG PET/CT&#xD;
      (3 months after treatment and toxicity scoring at 6 weeks, 3 months, 6 months, 1 year, 1.5&#xD;
      years and 3 years after radiotherapy (in addition to the routine follow-up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late toxicity - mucosal ulcer</measure>
    <time_frame>1 year</time_frame>
    <description>The study will be stopped if ≥ 3 patients experience late toxicity as assessed by CTCAE v5.0; mucosal ulcers grade ≥ 3 without healing within the first year after radiotherapy. This endpoint will be assessed by clinical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute or late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Any life-threatening toxicity (CTCAE v5.0) related to radiotherapy. This endpoint will be assessed by clinical examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>&lt; 3 months after radiotherapy</time_frame>
    <description>CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional control</measure>
    <time_frame>3 years</time_frame>
    <description>FDG PET/CT at 3 months. Imaging thereafter if clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
    <description>FDG PET/CT at 3 months. Imaging thereafter if clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Date from central registry.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Dose painting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose painting</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FDG-PET guided dose painting</intervention_name>
    <description>The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.</description>
    <arm_group_label>Dose painting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically or cytologically verified invasive squamous cell carcinoma of the head and&#xD;
        neck region; Sinonasal, oral cavity, hypopharynx cancer, larynx cancer, HPV-unrelated (p16&#xD;
        negative and/or HPV DNA negative) oropharyngeal cancer and TNM (primary tumor, regional&#xD;
        nodes, metastasis) stage T4 any N M0 HPV-related (p16 positive and/or HPV DNA positive)&#xD;
        oropharyngeal cancer.&#xD;
&#xD;
        Patients planned for standard curative treatment (radical radiotherapy with or without&#xD;
        concomitant chemotherapy, with or without nimorazole hypoxic cell radiosensitizer) Planned&#xD;
        treatment at the Oslo University Hospital Age &gt; 18 years WHO (World Health Organization)&#xD;
        performance status 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        TNM (primary tumor, regional nodes, metastasis) stage cT1 cN0-N1 cM0 Glottic cancer cT1-T2&#xD;
        cN0 cM0 HPV-related oropharyngeal carcinoma cT1-T3 (any N) Cancer in the soft palate&#xD;
        Diabetes mellitus Use of anticoagulant (or platelet inhibitor) Active smoking and/or&#xD;
        alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einar Dale, MD PhD</last_name>
    <phone>+4722934000</phone>
    <email>eindal@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Einar Dale, MD PhD</last_name>
      <phone>+4722934000</phone>
      <email>eindal@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Einar Dale</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Dose painting</keyword>
  <keyword>18F-FDG</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

